Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon‐independent manner

Thalidomide and its derivatives, lenalidomide and pomalidomide (also known as IMiDs), have significantly changed the treatment landscape of multiple myeloma, and the recent discovery of cereblon (CRBN) as their direct biological target has led to a deeper understanding of their complex mechanism of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Oncol
Main Authors: Dimopoulos, Konstantinos, Søgaard Helbo, Alexandra, Fibiger Munch‐Petersen, Helga, Sjö, Lene, Christensen, Jesper, Sommer Kristensen, Lasse, Asmar, Fazila, Hermansen, Niels Emil Ulrich, O'Connel, Casey, Gimsing, Peter, Liang, Gangning, Grønbæk, Kirsten
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2017
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5792743/
https://ncbi.nlm.nih.gov/pubmed/29130642
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12157
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados